Braftovi OverviewEncorafenib, also known as Braftovi and LGX818 is a drug for the treatment of certain melanomas. It is a small molecule BRAF inhibitor  that targets key enzymes in the MAPK signaling pathway. This pathway occurs in many different cancers including melanoma and coloerectal cancers. The substance was being developed by Novartis and then by Array BioPharma. In June 2018 it was approved by the FDA in combination with binimetinib for the treatment of patients ...
Read more Braftovi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Encorafenib
Recent Braftovi Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Capsule: 50mg, 75mg
NDC Database Records for Braftovi: (2 results)Sorted by National Drug Code
- 70255-020 Braftovi 50 mg Oral Capsule by Array Biopharma Inc.
- 70255-025 Braftovi 75 mg Oral Capsule by Array Biopharma Inc.